These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24130351)

  • 41. Impaired endothelium-dependent vasodilation in the brachial artery in variant angina pectoris and the effect of intravenous administration of vitamin C.
    Hamabe A; Takase B; Uehata A; Kurita A; Ohsuzu F; Tamai S
    Am J Cardiol; 2001 May; 87(10):1154-9. PubMed ID: 11356389
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes.
    Deane AM; Summers MJ; Zaknic AV; Chapman MJ; Fraser RJ; Di Bartolomeo AE; Wishart JM; Horowitz M
    Crit Care; 2011; 15(1):R35. PubMed ID: 21255422
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia.
    Ryan AS; Egan JM; Habener JF; Elahi D
    J Clin Endocrinol Metab; 1998 Jul; 83(7):2399-404. PubMed ID: 9661618
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus.
    McCormick LM; Heck PM; Ring LS; Kydd AC; Clarke SJ; Hoole SP; Dutka DP
    Cardiovasc Diabetol; 2015 Aug; 14():102. PubMed ID: 26253538
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment.
    Larsen J; Hylleberg B; Ng K; Damsbo P
    Diabetes Care; 2001 Aug; 24(8):1416-21. PubMed ID: 11473079
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog.
    Hövelmann U; Bysted BV; Mouritzen U; Macchi F; Lamers D; Kronshage B; Møller DV; Heise T
    Diabetes Care; 2018 Mar; 41(3):531-537. PubMed ID: 29273578
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes.
    Meier JJ; Weyhe D; Michaely M; Senkal M; Zumtobel V; Nauck MA; Holst JJ; Schmidt WE; Gallwitz B
    Crit Care Med; 2004 Mar; 32(3):848-51. PubMed ID: 15090972
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Taurine rescues vascular endothelial dysfunction in streptozocin-induced diabetic rats: correlated with downregulation of LOX-1 and ICAM-1 expression on aortas.
    Wang LJ; Yu YH; Zhang LG; Wang Y; Niu N; Li Q; Guo LM
    Eur J Pharmacol; 2008 Nov; 597(1-3):75-80. PubMed ID: 18796303
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Supplementation with vitamins C and E improves arterial stiffness and endothelial function in essential hypertensive patients.
    Plantinga Y; Ghiadoni L; Magagna A; Giannarelli C; Franzoni F; Taddei S; Salvetti A
    Am J Hypertens; 2007 Apr; 20(4):392-7. PubMed ID: 17386345
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
    Creutzfeldt WO; Kleine N; Willms B; Orskov C; Holst JJ; Nauck MA
    Diabetes Care; 1996 Jun; 19(6):580-6. PubMed ID: 8725855
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Randomized clinical trial on acute effects of i.v. iron sucrose during haemodialysis.
    Garcia-Fernandez N; Echeverria A; Sanchez-Ibarrola A; Páramo JA; Coma-Canella I
    Nephrology (Carlton); 2010 Mar; 15(2):178-83. PubMed ID: 20470276
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.
    Dupre J
    Regul Pept; 2005 Jun; 128(2):149-57. PubMed ID: 15780434
    [TBL] [Abstract][Full Text] [Related]  

  • 53. GLP-1R agonist therapy for diabetes: benefits and potential risks.
    Samson SL; Garber A
    Curr Opin Endocrinol Diabetes Obes; 2013 Apr; 20(2):87-97. PubMed ID: 23403741
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relationship between Optimum Mini-doses of Glucagon and Insulin Levels when Treating Mild Hypoglycaemia in Patients with Type 1 Diabetes - A Simulation Study.
    Ranjan A; Wendt SL; Schmidt S; Madsbad S; Holst JJ; Madsen H; Knudsen CB; Jørgensen JB; Nørgaard K
    Basic Clin Pharmacol Toxicol; 2018 Mar; 122(3):322-330. PubMed ID: 28922582
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reactive hypoglycaemia following GLP-1 infusion in pancreas transplant recipients.
    Rickels MR; Naji A
    Diabetes Obes Metab; 2010 Aug; 12(8):731-3. PubMed ID: 20590751
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intra-arterial vitamin C prevents endothelial dysfunction caused by ischemia-reperfusion.
    Pleiner J; Schaller G; Mittermayer F; Marsik C; MacAllister RJ; Kapiotis S; Ziegler S; Ferlitsch A; Wolzt M
    Atherosclerosis; 2008 Mar; 197(1):383-91. PubMed ID: 17645881
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.
    Hare KJ
    Dan Med Bull; 2010 Sep; 57(9):B4181. PubMed ID: 20816021
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vitamin C improves resistance but not conduit artery endothelial function in patients with chronic renal failure.
    Cross JM; Donald AE; Nuttall SL; Deanfield JE; Woolfson RG; Macallister RJ
    Kidney Int; 2003 Apr; 63(4):1433-42. PubMed ID: 12631359
    [TBL] [Abstract][Full Text] [Related]  

  • 59. No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Diabet Med; 2001 Feb; 18(2):144-9. PubMed ID: 11251679
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The synergistic effect of valsartan and LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] on vascular oxidative stress and inflammation in type 2 diabetic mice.
    Shen M; Sun D; Li W; Liu B; Wang S; Zhang Z; Cao F
    Exp Diabetes Res; 2012; 2012():146194. PubMed ID: 22474415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.